ChemoMetec Achieves Strong Financial Results for H1 2024/25
ChemoMetec has released its interim report showcasing an impressive performance for the first half of the 2024/25 financial year, reflecting robust growth in both revenue and earnings. The company registered revenue of DKK 251.5 million, marking a significant 26% increase compared to the previous year.
CEO Insights on Growth Factors
CEO Martin Helbo Behrens emphasized the company's strategic focus on enhancing commercial sales alongside a wave of new major orders for its innovative XcytoMatic instruments. The ongoing validation processes initiated earlier in the year significantly contributed to this growth. As the market for cell and gene therapy continues to evolve, ChemoMetec is placing greater emphasis on its automation solutions to meet the increasing demands of its customer base.
Launch and Development of XcytoMatic Instruments
The introduction of the XcytoMatic products has generated considerable interest in the marketplace. ChemoMetec is proactively collaborating with clients to create automated solutions that advance cell and gene therapies. Although the company anticipates a deceleration in growth during the year’s second half, it plans to broaden its validations across a diverse customer portfolio to sustain engagement and sales momentum.
Upgrades and New Innovations
Recognizing a promising market opportunity, ChemoMetec is expanding its XcytoMatic platform with the development of a new instrument, the XcytoMatic 50. This new addition will enhance the integration and automation of cell analysis processes by supporting the microplate format. Such innovations demonstrate ChemoMetec's commitment to leading advancements in bioprocessing and therapy solutions.
Financial Highlights from H1 2024/25
- Revenue for Q2 2024/25 surged by 26% to DKK 135.9 million.
- Instrument sales skyrocketed by 42% in the same period, reaching DKK 87.5 million, with the XcytoMatic platform accounting for DKK 20.3 million of total sales.
- Consumables and services also saw growth of 18% and 22%, contributing significantly to overall revenue.
- The company's core Life Science Business (LCB) reported a remarkable 29% revenue increase, emphasizing ChemoMetec's strengths in research and therapy segments.
- ChemoMetec achieved an EBITDA of DKK 135.2 million, reflecting a 45% year-on-year increase and a solid EBITDA margin of 54%.
- Development efforts for the XcytoMatic 50 instrument began in the first half, with a focus on market readiness.
Strategic Acquisition and Future Outlook
In a significant move for innovation, ChemoMetec has acquired Belgian-based Ovizio Imaging Systems for technology expansion, enhancing its capabilities in online cell counting and related services. This strategic acquisition allows the company to leverage new technologies to broaden its product offerings.
ChemoMetec's performance in the first half exceeded initial expectations, leading to three upward revisions in revenue and EBITDA guidance. The current projections suggest revenue between DKK 470-490 million and EBITDA of DKK 250-260 million for the entirety of the financial year.
Join the Discussion: Conference Call Announcement
The company will host a conference call to discuss its interim report on an upcoming Thursday. CEO Martin Helbo Behrens and CFO Kim Nicolajsen will present key insights regarding the financial outcomes and growth strategies. All interested parties are invited to register for the call via email.
About ChemoMetec A/S
Founded in 1997, ChemoMetec focuses on developing advanced instruments for cell counting and various biological measurements. The company serves the pharmaceutical, biotech, and agricultural industries globally, partnering with leading pharmaceutical firms to enhance research and therapeutic efficiency.
Frequently Asked Questions
What financial performance did ChemoMetec achieve in H1 2024/25?
ChemoMetec reported a revenue of DKK 251.5 million, marking a 26% increase compared to the previous year.
What is the significance of the XcytoMatic instruments?
The XcytoMatic instruments are pivotal in enhancing automation and efficiency in cell and gene therapy processes, leading to increased sales and positive customer feedback.
How does ChemoMetec's acquisition of Ovizio benefit the company?
The acquisition of Ovizio enhances ChemoMetec's capabilities in online and label-free cell counting, broadening their technology and service offerings.
What growth expectations does ChemoMetec have for the second half?
ChemoMetec expects growth to continue but at a slower pace due to extended validation processes and the nature of investment decisions made by customers.
How can one follow the upcoming conference call?
To participate in the conference call, interested individuals can register via email, as announced in the report.
